ZYME: FDA approval, robust pipeline, and strategic partnerships drive growth and shareholder value
FDA approval of zanidatamab in HER2-positive gastric cancer establishes a new standard of care and drives significant royalty and milestone potential. The pipeline is advancing with multiple phase III readouts and innovative trispecific and ADC programs, while disciplined capital allocation and str…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.